Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Mamo

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 22, 2011
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosisCamilo de la Fuente-Sandoval, Pablo León-Ortiz, Rafael Favila, et al.
Plos One|April 21, 2010
Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late lifeChristina Ting, Tarek K Rajji, Zahinoor Ismail, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 31, 2014
Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNOFernando Caravaggio, Shinichiro Nakajima, Carol Borlido, et al.
Biological Psychiatry|August 12, 2011
Exploring the neural correlates of delusions of referenceMahesh Menon, Taylor W Schmitz, Adam K Anderson, et al.
Human Brain Mapping|May 15, 2007
Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humansAriel Graff-Guerrero, Matthaeus Willeit, Nathalie Ginovart, et al.
Archives of General Psychiatry|June 3, 2009
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNOAriel Graff-Guerrero, David Mamo, C M Shammi, et al.
Psychopharmacology|February 19, 2013
Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET studyTakefumi Suzuki, Ariel Graff-Guerrero, Hiroyuki Uchida, et al.
Psychopharmacology|June 4, 2008
The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonistSridhar Natesan, Greg E Reckless, Karen B L Barlow, et al.
The Journal of Clinical Psychiatry|September 13, 2012
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophreniaSaeko Ikai, Gary Remington, Takefumi Suzuki, et al.
British Journal of Clinical Pharmacology|February 3, 2022
MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patientsMohamed Ismail, Thomas Straubinger, Hiroyuki Uchida, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 22, 2011
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosisCamilo de la Fuente-Sandoval, Pablo León-Ortiz, Rafael Favila, et al.
Plos One|April 21, 2010
Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late lifeChristina Ting, Tarek K Rajji, Zahinoor Ismail, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 31, 2014
Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNOFernando Caravaggio, Shinichiro Nakajima, Carol Borlido, et al.
Biological Psychiatry|August 12, 2011
Exploring the neural correlates of delusions of referenceMahesh Menon, Taylor W Schmitz, Adam K Anderson, et al.
Human Brain Mapping|May 15, 2007
Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humansAriel Graff-Guerrero, Matthaeus Willeit, Nathalie Ginovart, et al.
Archives of General Psychiatry|June 3, 2009
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNOAriel Graff-Guerrero, David Mamo, C M Shammi, et al.
Psychopharmacology|February 19, 2013
Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET studyTakefumi Suzuki, Ariel Graff-Guerrero, Hiroyuki Uchida, et al.
Psychopharmacology|June 4, 2008
The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonistSridhar Natesan, Greg E Reckless, Karen B L Barlow, et al.
The Journal of Clinical Psychiatry|September 13, 2012
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophreniaSaeko Ikai, Gary Remington, Takefumi Suzuki, et al.
British Journal of Clinical Pharmacology|February 3, 2022
MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patientsMohamed Ismail, Thomas Straubinger, Hiroyuki Uchida, et al.
Pageof 4